Myrna weissman biography of martin luther

  • Myrna M. Weissman.
  • Seven researchers in the growing field of the cognitive science of religion recently claimed to have documented the unique neural correlates of spirituality.
  • Keywords: African Americans; Civil Rights; Civil Rights Movements; Governors; History; King, Martin Luther, Jr., 1929 1968; Moore, Daniel.

    • •

    Dissecting the Shared Genetic Architecture of Suicide Attempt, Psychiatric Disorders, and Known Risk Factors

    Authors

    Niamh Mullins  1 , JooEun Kang  2 , Adrian I Campos  3 , Jonathan R I Coleman  4 , Alexis C Edwards  5 , Hanga Galfalvy  6 , Daniel F Levey  7 , Adriana Lori  8 , Andrey Shabalin  9 , Anna Starnawska  10 , Mei-Hsin Su  11 , Hunna J Watson  12 , Mark Adams  13 , Swapnil Awasthi  14 , Michael Gandal  15 , Jonathan D Hafferty  13 , Akitoyo Hishimoto  16 , Minsoo Kim  15 , Satoshi Okazaki  17 , Ikuo Otsuka  18 , Stephan Ripke  19 , Erin B Ware  20 , Andrew W Bergen  21 , Wade H Berrettini  22 , Martin Bohus  23 , Harry Brandt  24 , Xiao Chang  25 , Wei J Chen  26 , Hsi-Chung Chen  27 , Steven Crawford  24 , Scott Crow  28 , Emily DiBlasi  9 , Philibert Duriez  29 , Fernando Fernández-Aranda  30 , Manfred M Fichter  31 , Steven Gallinger  32

  • myrna weissman biography of martin luther

    • •

    . Author manuscript; available in PMC: 2018 Aug 20.

    Published in final edited form as: J Psychiatr Res. 2016 Mar 15;78:11–23. doi: 10.1016/j.jpsychires.2016.03.001

    Abstract

    Remission rates for Major Depressive Disorder (MDD) are low and unpredictable for any given antidepressant. No biological or clinical marker has demonstrated sufficient ability to match individuals to efficacious treatment. Biosignatures developed from the systematic exploration of multiple biological markers, which optimize treatment selection for individuals (moderators) and provide early indication of ultimate treatment response (mediators) are needed. The rationale and design of a multi-site, placebo-controlled randomized clinical trial of sertraline examining moderators and mediators of treatment response is described. The target sample is 400 participants with early onset (<30 years) recurrent MDD. Non-responders to an 8-week trial are switched double blind to either bupropion (for sertraline non-responders) or sertraline (for placebo non-responders) for an additional 8 weeks. Clinical moderators include anxious depression, early trauma, gender, melancholic and atypical depression, anger attacks, Axis II disorder, hypersomnia/fatigue, and chronicity of depression. Biological moderator and medi

    •

    Start Over|

    « Previous | 401 - 500 sell like hot cakes 1,570 | Next »

    Search Results